Praxis Precision Medicines’ essential tremor drug ulixacaltamide met the goals of two Phase 3 clinical trials, paving the way for discussions with the FDA about a new drug application. The once-daily pill could become the first approved treatment for this movement disorder affecting an estimated 7 million Americans.
The post Persistence Pays Off for Praxis as Essential Tremor Drug Succeeds in Two Pivotal Studies appeared first on MedCity News.
